Sangamo Therapeutics Gestione
Criteri Gestione verificati 2/4
Sangamo Therapeutics Il CEO è Sandy Macrae, nominato in Jun2016, e ha un mandato di 10.17 anni. la retribuzione annua totale è $ 2.60M, composta da 28.7% di stipendio e 71.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.4% delle azioni della società, per un valore di $ 184.68K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.1 anni e 6.8 anni.
Informazioni chiave
Sandy Macrae
Amministratore delegato
US$2.6m
Compenso totale
| Percentuale dello stipendio del CEO | 28.69% |
| Mandato del CEO | 10.2yrs |
| Proprietà del CEO | 0.4% |
| Durata media del management | 4.1yrs |
| Durata media del Consiglio di amministrazione | 6.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Jun 25
SGMO: Bankruptcy Restructuring Will Set Up Fabry-Focused Recovery Potential
The analyst price target for Sangamo Therapeutics has been cut from $10 to $5 as analysts factor in higher funding and partnership uncertainty related to completing the Fabry biologics license application and progressing the neurology pipeline. What’s in the News for Sangamo Therapeutics Sangamo Therapeutics filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on June 23, 2026, listing assets and liabilities each in the range of US$100 million to US$500 million, with Richards, Layton & Finger, P.A. and Cooley LLP as legal counsel, and MERU, LLC, Raymond James & Associates, Inc., and Kurtzman Carson Consultants LLC d/b/a Verita Global engaged as advisors and claims agent.
Aggiornamento narrativa • Jun 05
SGMO: Fabry Filing Progress Will Support Neurology Pipeline Despite Funding Uncertainty
Narrative Update: Sangamo Therapeutics Price Target Revision Analysts have cut their price target on Sangamo Therapeutics from $10 to $5. This reflects concerns about the uncertainty around securing a commercialization partner or sufficient funding to complete the Fabry biologics license application process and continue developing the neurology pipeline, even as the underlying regulatory and clinical thesis for isaralgagene civaparvovec remains in place.Aggiornamento narrativa • Apr 20
SGMO: Fabry Filing Progress Will Offset Going Concern And Liquidity Fears
Analysts have updated their price target on Sangamo Therapeutics to reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. The new fair value estimate remains at $1.00, in line with the prior $1.00 target.Aggiornamento narrativa • Apr 06
SGMO: Fabry Gene Therapy Filing And Diagnostic Will Drive Future Upside
Analysts have trimmed their price target on Sangamo Therapeutics from $1.25 to $1.00, citing updated assumptions for revenue growth, profit margins and future P/E that have reset expectations for the stock. What's in the News Sangamo reported unaudited impairment charges on long lived assets of US$13,235,000 for the fourth quarter ended December 31, 2025, which affects reported earnings quality for that period (Key Developments).Aggiornamento narrativa • Mar 22
SGMO: Fabry Gene Therapy Filing And Kidney Endpoint Will Drive Upside
Analysts have adjusted their price target on Sangamo Therapeutics to $1.25, with the change based on updated views on discount rate, revenue growth, profit margin, and future P/E assumptions, even though the fair value estimate itself remains $1.25. What's in the News Sangamo started a rolling submission of a Biologics License Application to the FDA for isaralgagene civaparvovec (ST-920), an investigational one time gene therapy for adults with Fabry disease, and has submitted the preclinical and clinical modules for review (Key Developments).Aggiornamento narrativa • Mar 08
SGMO: Accelerated Approval Pathway On Kidney Data Will Drive Bullish Upside
Analysts have set their price target for Sangamo Therapeutics at $1.25, based on updated assumptions for discount rate, revenue growth, profit margin, and future P/E, while the fair value estimate remains unchanged at $1.25. What's in the News Sangamo reported detailed data from the registrational Phase 1/2 STAAR study of its gene therapy candidate isaralgagene civaparvovec (ST 920) for Fabry disease.Aggiornamento narrativa • Feb 22
SGMO: Accelerated Approval On Kidney Function Data Will Drive Bullish Thesis
Analysts have maintained their average price target for Sangamo Therapeutics at $1.25. This reflects minor adjustments to their models, including slightly different assumptions for discount rate, revenue growth, profit margin, and forward P/E, rather than a change in their overall view.Aggiornamento narrativa • Feb 07
SGMO: Accelerated Approval Using EGFR Slope Will Support Bullish Outlook
Analysts have nudged their fair value estimate for Sangamo Therapeutics higher to $1.25 from $1.00, citing updated assumptions around revenue growth, profit margins, discount rates and a higher future P/E multiple. What's in the News Sangamo Therapeutics completed a follow on equity offering totaling approximately US$24.8 million, issuing 35,190,292 shares of common stock at US$0.4719 per share and 17,787,033 pre funded warrants at US$0.4619 per warrant (Key Developments).Articolo di analisi • Feb 03
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have had a really impressive month, gaining 29% after a shaky period...
Aggiornamento narrativa • Jan 23
SGMO: Accelerated Approval Pathway Will Drive Upside Despite Downgrade Through 2026
Narrative Update Analysts have cut their price target on Sangamo Therapeutics from US$5 to US$1, citing the recent downgrade to Equal Weight and a wait for more clarity on a potential Fabry deal, despite the FDA reaffirming an accelerated approval path and the company extending its cash runway into Q1 2026. Analyst Commentary Recent research paints a mixed picture for Sangamo Therapeutics, with the lower price target and rating downgrade balanced against some supportive clinical and balance sheet signals.Aggiornamento narrativa • Jan 09
SGMO: Accelerated Approval Path Using EGFR Slope Will Drive Future Upside
Analysts have trimmed their 12 month price target on Sangamo Therapeutics to US$1 from US$5, citing a wait and see stance on Fabry deal clarity and the current cash runway into Q1 2026, despite the reaffirmed accelerated approval path using eGFR slope. Analyst Commentary Bearish analysts are signaling a more cautious stance on Sangamo Therapeutics after the recent Q3 update, with the sharp cut in the 12 month price target standing out as a key marker of reduced confidence.Aggiornamento narrativa • Dec 25
SGMO: Accelerated Approval Pathway And Extended Runway Will Support Upside Through 2026
Analysts have modestly reduced their price target on Sangamo Therapeutics to $1 from $5, citing a more cautious stance as they await greater clarity on potential Fabry partnership developments, despite the extended cash runway and reaffirmed accelerated approval pathway. Analyst Commentary Analysts note that the downgrade and lower price target reflect a shift toward a more balanced risk reward profile, with recent catalysts prompting both supportive and cautious views on Sangamo Therapeutics.Aggiornamento narrativa • Dec 11
SGMO: Accelerated Approval Pathway Is Expected To Drive Upside Through 2026
Analysts have lowered their price target on Sangamo Therapeutics from $5.00 to $1.00 per share, citing a more cautious stance as they await greater clarity on a potential Fabry partnership, despite an extended cash runway and a reaffirmed accelerated approval path. Analyst Commentary Analysts are reassessing Sangamo Therapeutics with a more balanced view, emphasizing both the company’s de-risked regulatory path and the uncertainties that could weigh on execution and valuation.Aggiornamento narrativa • Nov 27
SGMO: FDA Accelerated Pathway Will Extend Bullish Momentum Into 2026
Analysts have lowered Sangamo Therapeutics’ price target from $5 to $1, citing uncertainty around future partnership deals. This is despite recent regulatory updates and an extended cash runway.Articolo di analisi • Nov 23
Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have had a horrible month, losing 33% after a relatively good period...Aggiornamento narrativa • Nov 08
SGMO: FDA Approval Path Will Drive Bullish Outlook Into 2026
Analysts have lowered their price target for Sangamo Therapeutics from $5 to $1. They cited a cautious outlook, pending greater clarity on a Fabry collaboration and updated guidance following the company's latest quarterly report.Articolo di analisi • Oct 07
There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 28% Share Price Rise
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have continued their recent momentum with a 28% gain in the last...Articolo di analisi • Sep 23
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Aggiornamento narrativa • Sep 21
FDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects
The sharp increase in Sangamo Therapeutics' consensus analyst price target is primarily driven by a significantly higher future P/E expectation, indicating greater anticipated earnings growth or improved sentiment, with the fair value rising from $2.62 to $4.10. What's in the News CFO Prathyusha Duraibabu resigned, effective October 1, to join a private AI company; no disagreements cited in her departure.Aggiornamento narrativa • Sep 06
FDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects
Sangamo Therapeutics' fair value has been revised downward, primarily reflecting meaningful declines in both its forward P/E multiple and net profit margin, resulting in a lower consensus price target of $2.62. What's in the News Sangamo presented detailed data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), its investigational gene therapy for adults with Fabry disease, showing a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year in all patients followed at least 12 months.Articolo di analisi • Jul 24
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Those holding Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares would be relieved that the share price has rebounded...
Nuova narrativa • Apr 01
Neurology IND And Fabry Agreements Will Transform Treatment
Strategic partnerships and collaborations position Sangamo as a key player, enhancing revenue potential through non-dilutive capital and licensing agreements.Articolo di analisi • Mar 04
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares are down a considerable 25% in...Articolo di analisi • Dec 08
Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30%
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have retraced a considerable 30% in the last month, reversing a fair...Articolo di analisi • Nov 20
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders will have a reason to smile today, with the analysts making...Articolo di analisi • Oct 23
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have continued their recent momentum with a 26% gain in the last...Seeking Alpha • Oct 21
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?
Summary Sangamo Therapeutics, Inc.'s stock surged after positive updates on two lead assets, giro-vec and STAC-BBB, with potential for significant milestone payments and partnerships. The upcoming isa-vec deal could be transformative, potentially securing Sangamo's financial stability and pushing its valuation towards $1 billion. Despite recent gains, high volatility and financial risks make SGMO a speculative investment, suitable only for risk-tolerant investors. Key risks include potential setbacks in giro-vec and isa-vec developments, which could impact Sangamo's cash flow and overall valuation. Read the full article on Seeking AlphaArticolo di analisi • Aug 03
There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • Jul 23
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Summary Sangamo Therapeutics, Inc. is almost out of cash, and as such, at risk of bankruptcy. Therefore, investing in this company is not a good idea for most investors. 3 of its assets have updates coming over the next 1–6 months that could realistically bring in a combination of ~$1B of cash & milestones over the next 12–18 months. Due to its history of burning cash and not being able to get a drug approved yet, Sangamo Therapeutics's stock price closed Monday, 07/22/24 at $0.395/s or a valuation of ~$82M. Below, I will discuss why I think the company is going to make it and possibly deliver 5-10x over the next 6–12 months. Read the full article on Seeking AlphaArticolo di analisi • Jun 19
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop
Unfortunately for some shareholders, the Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) share price has dived 35% in the...Articolo di analisi • May 29
We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package
Key Insights Sangamo Therapeutics' Annual General Meeting to take place on 4th of June CEO Sandy Macrae's total...Articolo di analisi • May 14
This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year
Shareholders in Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) may be thrilled to learn that the analysts have just...Articolo di analisi • Mar 23
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have retraced a considerable 36% in the last month, reversing a fair...Articolo di analisi • Mar 16
Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Today is shaping up negative for Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders, with the analysts delivering...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$123m |
| Dec 31 2025 | US$3m | US$745k | -US$123m |
| Sep 30 2025 | n/a | n/a | -US$109m |
| Jun 30 2025 | n/a | n/a | -US$65m |
| Mar 31 2025 | n/a | n/a | -US$79m |
| Dec 31 2024 | US$2m | US$716k | -US$98m |
| Sep 30 2024 | n/a | n/a | -US$135m |
| Jun 30 2024 | n/a | n/a | -US$248m |
| Mar 31 2024 | n/a | n/a | -US$328m |
| Dec 31 2023 | US$2m | US$716k | -US$258m |
| Sep 30 2023 | n/a | n/a | -US$250m |
| Jun 30 2023 | n/a | n/a | -US$199m |
| Mar 31 2023 | n/a | n/a | -US$127m |
| Dec 31 2022 | US$5m | US$709k | -US$192m |
| Sep 30 2022 | n/a | n/a | -US$178m |
| Jun 30 2022 | n/a | n/a | -US$172m |
| Mar 31 2022 | n/a | n/a | -US$176m |
| Dec 31 2021 | US$5m | US$689k | -US$178m |
| Sep 30 2021 | n/a | n/a | -US$181m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$124m |
| Dec 31 2020 | US$4m | US$682k | -US$121m |
| Sep 30 2020 | n/a | n/a | -US$76m |
| Jun 30 2020 | n/a | n/a | -US$102m |
| Mar 31 2020 | n/a | n/a | -US$96m |
| Dec 31 2019 | US$4m | US$662k | -US$95m |
Compensazione vs Mercato: La retribuzione totale di Sandy ($USD 2.60M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 657.11K ).
Compensazione vs guadagni: La retribuzione di Sandy è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Sandy Macrae (63 yo)
10.2yrs
Mandato
US$2,596,918
Compensazione
Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 10.2yrs | US$2.60m | 0.40% $ 184.7k | |
| Senior VP | 5yrs | US$1.10m | 0.14% $ 63.7k | |
| Senior VP & Chief Development Officer | 7.6yrs | US$1.12m | 0.060% $ 28.0k | |
| Interim CFO and Principal Financial & Accounting Officer | less than a year | Nessun dato | 0.049% $ 22.7k | |
| Chief Technical Officer | 3.3yrs | Nessun dato | Nessun dato | |
| VP and Head of Business Development & Alliance Management | 2.7yrs | Nessun dato | Nessun dato | |
| Scientist II - Discovery & Translational Research | no data | Nessun dato | Nessun dato |
4.1yrs
Durata media
57yo
Età media
Gestione esperta: Il team dirigenziale di SGMO.Q è considerato esperto (durata media dell'incarico 4.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 10.2yrs | US$2.60m | 0.40% $ 184.7k | |
| Independent Chairwoman of the Board | 12.2yrs | US$117.66k | 0.021% $ 9.8k | |
| Independent Director | 10.2yrs | US$92.66k | 0.018% $ 8.4k | |
| Member of Scientific Advisory Board | 6.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 6.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 6.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 6.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 6.8yrs | Nessun dato | Nessun dato | |
| Independent Director | 8.2yrs | US$87.66k | 0.019% $ 8.6k | |
| Member of Scientific Advisory Board | 6.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 6.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 6.8yrs | Nessun dato | Nessun dato |
6.8yrs
Durata media
68.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SGMO.Q sono considerati esperti (durata media dell'incarico 6.8 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/09 00:28 |
| Prezzo dell'azione a fine giornata | 2026/08/07 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Sangamo Therapeutics, Inc. è coperta da 16 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Gregory Harrison | BofA Global Research |
| Douglas Buchanan | Brean Capital Historical (Janney Montgomery) |
| John Newman | Citizens JMP Securities, LLC |